What is the 13F Pro Quality Score for PIII?

13F Pro ranks P3 Health Partners Inc. (PIII) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PIII's current score at https://13fpro.ai/research/PIII (free sign-up required for the full ranking).

Where does 13F Pro source PIII data?

All P3 Health Partners Inc. fundamentals and ownership data come directly from SEC EDGAR. P3 Health Partners Inc. files with the SEC under CIK 1832511. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PIII in?

P3 Health Partners Inc. (PIII) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PIII research updated on 13F Pro?

PIII's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

P3 Health Partners Inc.(PIII)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1832511 PIII stock profile & AI dashboard →

13F Pro Quality Score

38.7/100

Rank #2,001 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

53.5/100

Profitability

30.8/100

Balance Sheet

16.5/100

Earnings Quality

30.0/100

Free Cash Flow

22.3/100

Institutional Flow

40.5/100

Revenue Scale

56.8/100

Dilution Risk

79.2/100

PIII Stock Analysis & AI Quality Score

AI stock analysis and institutional research for P3 Health Partners Inc. (PIII), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PIII at 38.7/100 on a 32-signal composite quality model, placing it at rank #2,001 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (16.5) and free cash flow (22.3), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), P3 Health Partners Inc. reports quarterly revenue of $386.4M, net income of $1.2M, free cash flow of $-27.5M. Top institutional holders of PIII by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, Trinity Financial Advisors, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. PIII trades on the Nasdaq exchange and files with the SEC under CIK 1832511. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PIII daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for P3 Health Partners Inc. directly from SEC EDGAR. P3 Health Partners Inc.'s 13F Pro composite quality score has ranged between 35 and 47 since 2022, currently 38.7 — a stable long-term trajectory across 21 quarterly and live scoring snapshots.

Revenue

Q1 2026

$386.4M

Net Income

Q1 2026

$1.2M

Free Cash Flow

Q1 2026

$-27.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-2.8% YoY

$1.46BFY 2025

FY22 $1.05BFY23 $1.27BFY24 $1.50BFY25 $1.46B

Net Income

-8.9% YoY

$-147.9MFY 2025

FY22 $-270.1MFY23 $-57.8MFY24 $-135.8MFY25 $-147.9M

Operating Income

+15.7% YoY

$-270.3MFY 2025

FY22 $-1.56BFY23 $-167.9MFY24 $-320.7MFY25 $-270.3M

EPS (Diluted)

+16.3% YoY

$-45.26FY 2025

FY22 $-6.50FY23 $-0.63FY24 $-54.06FY25 $-45.26

Total Assets

-16.2% YoY

$656.6MFY 2025

FY22 $876.6MFY23 $861.0MFY24 $783.4MFY25 $656.6M

Total Debt

+48.5% YoY

$273.4MFY 2025

FY22 $94.4MFY23 $108.3MFY24 $184.1MFY25 $273.4M

Op. Cash Flow

+17.2% YoY

$-91.2MFY 2025

FY22 $-126.0MFY23 $-76.0MFY24 $-110.1MFY25 $-91.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$1.46B -2.8%	$1.50B +18.5%	$1.27B +20.7%	$1.05B +113.7%	$491.1M +237.5%	$145.5M
Net Income	$-147.9M -8.9%	$-135.8M -135.1%	$-57.8M +78.6%	$-270.1M -760.0%	$-31.4M +25.2%	$-42.0M
Operating Income	$-270.3M +15.7%	$-320.7M -90.9%	$-167.9M +89.2%	$-1.56B -5360.1%	$-28.6M +27.7%	$-39.5M
EPS (Diluted)	$-45.26 +16.3%	$-54.06 -8481.0%	$-0.63 +90.3%	$-6.50	—	—
Total Assets	$656.6M -16.2%	$783.4M -9.0%	$861.0M -1.8%	$876.6M +723.6%	$106.4M	—
Total Debt	$273.4M +48.5%	$184.1M +69.9%	$108.3M +14.7%	$94.4M +71.0%	$55.2M	—
Operating Cash Flow	$-91.2M +17.2%	$-110.1M -44.9%	$-76.0M +39.7%	$-126.0M -412.4%	$-24.6M +13.0%	$-28.3M

AI Insight: PIII Financial Trends

P3 Health Partners swung to Q1 2026 profitability but revenue remains 1% below pre-decline levels amid sharply deteriorated leverage.

• Net income turned positive at $1M in Q1 2026 after eight consecutive loss quarters; operating income improved to $8M from $-88M in Q4 2025.

• Revenue contracted 11% from $388M in Q1 2024 to $386M in Q1 2026; operating cash flow remained negative at $-27M in latest quarter.

• Total debt surged 203% from $120M in Q1 2024 to $363M in Q1 2026; equity collapsed from $147M to negative $155M.

⚠ Leverage has become unsustainable: debt-to-equity ratio inverted into negative territory; company balance sheet now technically insolvent.

⚠ Profitability reversal appears fragile—single positive quarter after sustained losses; operating cash flow deterioration contradicts income recovery.

AI Insight: PIII Ratio Trends

P3 Health Partners swung to profitability in Q1 2026, posting positive operating margin of 2.1% after five consecutive loss-making quarters.

• Operating margin improved 28.9pp from Q4 2025 (-26.8%) to Q1 2026 (2.1%), first positive result since Q2 2024.

• ROIC turned positive at 9.1% in Q1 2026 versus -64.8% in Q3 2025, reversing sharp destruction of shareholder capital.

• Return on assets improved to 0.7% in Q1 2026 from -43.1% in Q4 2025, indicating better asset utilization.

⚠ Q4 2025 showed severe deterioration (-26.8% OpMargin, -43.1% ROA); Q1 2026 recovery may reflect seasonality or one-off adjustments rather than structural improvement.

⚠ Leverage spiked to 5.90 D/E in Q2 2025 from 0.80 in Q1 2024; latest quarter debt ratio unavailable—capital structure stability unclear.

⚠ TTM net profit margin of -8.6% remains negative; single-quarter profitability does not confirm sustained turnaround.

Get alerted when PIII's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for P3 Health Partners Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PIII

VANGUARD CAPITAL MANAGEMENT LLC
$217.5K70,627 sh
Trinity Financial Advisors LLC
$83.3K27,057 sh
GEODE CAPITAL MANAGEMENT, LLC
$79.8K25,900 sh
Diversified Trust Co
$62.6K20,316 sh
Corient Private Wealth LLC
$61.1K19,837 sh
NINE MASTS CAPITAL Ltd
$55.3K17,964 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$41.2K13,371 sh
BlackRock, Inc.
$33.6K10,920 sh
Lido Advisors, LLC
$33.1K10,748 sh
VANGUARD FIDUCIARY TRUST CO
$19.9K6,477 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$217.5K	70,627
Trinity Financial Advisors LLC	$83.3K	27,057
GEODE CAPITAL MANAGEMENT, LLC	$79.8K	25,900
Diversified Trust Co	$62.6K	20,316
Corient Private Wealth LLC	$61.1K	19,837
NINE MASTS CAPITAL Ltd	$55.3K	17,964
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$41.2K	13,371
BlackRock, Inc.	$33.6K	10,920
Lido Advisors, LLC	$33.1K	10,748
VANGUARD FIDUCIARY TRUST CO	$19.9K	6,477

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PIII on your watchlist

Track score changes the day P3 Health Partners Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PIII a good stock to buy?

13F Pro's AI-powered analysis of P3 Health Partners Inc. (PIII) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PIII are available on the PIII stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PIII?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PIII. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of P3 Health Partners Inc.'s investment landscape.